Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study

Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Subramaniam Srinivasan, Subramanian Pushkala, Sudhakar Subramanian, Nobunao Ikewaki, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, View ORCID ProfileSamuel JK Abraham
doi: https://doi.org/10.1101/2021.12.13.21267706
Kadalraja Raghavan
1Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for Advanced Rehabilitation and Education (JAICARE), Madurai, India
2Department of Paediatric Neurology, Kenmax Medical Service Private Limited, Madurai, India
3Department of Paediatric Neurology, Sarvee Integra Private Limited, Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vidyasagar Devaprasad Dedeepiya
4Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subramaniam Srinivasan
4Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subramanian Pushkala
5Department of Immunology, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, 600032, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudhakar Subramanian
6Department of Anesthesia and Pain service, Toronto Western Hospital, 399 Bathurst street Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobunao Ikewaki
7Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
8Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Iwasaki
9Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajappa Senthilkumar
10Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Senthilkumar Preethy
10Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel JK Abraham
4Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
9Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
11Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel JK Abraham
  • For correspondence: drsam@nichimail.jp drspp@nichimail.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder causing progressive muscle weakness and premature death. Steroids remain the mainstream approach for supportive care but have side effects; other targeted therapies and gene therapies are also being developed. As there is limited evidence on the use of disease-modifying nutritional supplement adjuncts in DMD, this pilot trial is to evaluate the effects of supplementation of Aureobasidium pullulans-derived 1,3-1,-6 beta glucan from the N-163 strain in young patients with DMD.

Methods Twenty-seven patients with Duchenne muscular dystrophy (DMD)—nine in the control arm (undergoing conventional therapies)—participated. The patients were divided into groups: those not administered steroids (Steroid -ve) (n = 5), those administered steroids (Steroid +ve) (n = 4), and 18 in the treatment arm (N-163 beta glucan supplement along with conventional therapies; N-163 Steroid –ve and N-163 Steroid +ve); they participated in the study for 45 days. Assessments of muscle function, disease status, and levels of IL-6, IL-13, TGF-β, creatinine kinase (CK), titin, TNF-α, haptoglobin, and dystrophin in the blood and myoglobin in the urine were performed at baseline and at the end of the study.

Results IL-6 showed a significant decrease in the N-163 Steroid -ve group, from a baseline value of 7.2 ± 1.2 pg/ml to 2.7 ± 0.03 pg/ml. IL-13 decreased in both treatment groups—from 157.76 ± 148.68 pg/ml to 114.08 ± 81.5 pg/ml (N-163 Steroid -ve) and from 289.56 ± 232.88 pg/ml to 255.56 ± 214.13 pg/ml (N-163 Steroid +ve). TGF-β levels showed a significant decrease in the N-163 Steroid –ve group, from a baseline value of 3302 ± 1895 ng/ml to 1325.66 ± 517 ng/ml post intervention. Dystrophin levels increased by up to 32% in both Steroid +ve and -ve groups. Medical research council (MRC) grading showed muscle strength improvement in 12 out of 18 patients (67%) in the treatment group and four out of nine (44%) subjects in the control group.

Conclusion Supplementation with the N-163 beta glucan food supplement produced disease-modifying beneficial effects: a significant decrease in inflammation and fibrosis markers, increase in dystrophin and improvement in muscle strength in DMD subjects over 45 days, thus making this a potential adjunct treatment for DMD after validation. A longer duration of follow-up and further research on the mechanism of action and commonalities with other diseases provoked by hyperactive inflammation and/or fibrosis may pave the way for their extended applications in other dystrophinopathies and neuroinflammatory diseases.

Trial registration Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5 May, 2021.

Competing Interest Statement

Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.

Clinical Trial

Clinical trials registry of India, CTRI/2021/05/033346

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • drkraghavan{at}nichimail.jp, dedeepiya_76{at}yahoo.co.in, masala76{at}gmail.com, pushkala66m{at}gmail.com, drsudhakar77{at}gmail.com, nikewaki{at}phoenix.ac.jp, miwasaki{at}yamanashi.ac.jp, rsk{at}nichimail.jp, drspp{at}nichimail.jp, drsam{at}nichimail.jp)

  • Conflicts of interest/Competing interests: Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.

  • Ethics Approval: The study was registered in Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5th May, 2021. The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.

  • Funding: No external funding was received for the study

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study
Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Subramaniam Srinivasan, Subramanian Pushkala, Sudhakar Subramanian, Nobunao Ikewaki, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham
medRxiv 2021.12.13.21267706; doi: https://doi.org/10.1101/2021.12.13.21267706
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study
Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Subramaniam Srinivasan, Subramanian Pushkala, Sudhakar Subramanian, Nobunao Ikewaki, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham
medRxiv 2021.12.13.21267706; doi: https://doi.org/10.1101/2021.12.13.21267706

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)